Korlyns Therapeutics Ltd 6215455 false 2024-06-01 2025-05-31 2025-05-31 The principal activity of the company is the distribution and licensing of generic pharmaceutical products and equipment. Digita Accounts Production Advanced 6.30.9574.0 true 6215455 2024-06-01 2025-05-31 6215455 2025-05-31 6215455 core:CurrentFinancialInstruments core:WithinOneYear 2025-05-31 6215455 bus:Micro-entities 2024-06-01 2025-05-31 6215455 bus:AuditExemptWithAccountantsReport 2024-06-01 2025-05-31 6215455 bus:FilletedAccounts 2024-06-01 2025-05-31 6215455 bus:SmallCompaniesRegimeForAccounts 2024-06-01 2025-05-31 6215455 bus:RegisteredOffice 2024-06-01 2025-05-31 6215455 bus:CompanySecretary1 2024-06-01 2025-05-31 6215455 bus:Director1 2024-06-01 2025-05-31 6215455 bus:PrivateLimitedCompanyLtd 2024-06-01 2025-05-31 6215455 countries:AllCountries 2024-06-01 2025-05-31 6215455 2023-06-01 2024-05-31 6215455 2024-05-31 6215455 core:CurrentFinancialInstruments core:WithinOneYear 2024-05-31 iso4217:GBP xbrli:pure

Registration number: 6215455

Korlyns Therapeutics Ltd
Unaudited Filleted Financial Statements
for the Year Ended 31 May 2025

[FRS 105 Micro Entities]
[FILLETED FOR FILING PURPOSES]

Korlyns Therapeutics Ltd

Contents

Company Information | 1
Balance Sheet | 2 to 3
Notes to the Unaudited Financial Statements | 2

Korlyns Therapeutics Ltd

Company Information

Director | C Iriajen

Company secretary | E Iriajen

Registered office | 10 Linkfield Lane Redhill Surrey RH1 1JL

Accountants | Tremaines Ltd East Wing, South Hill Paddockhurst Road Turners Hill West Sussex RH10 4SF

Korlyns Therapeutics Ltd

(Registration number: 6215455)
Balance Sheet as at 31 May 2025

| 2025 £ | 2024 £
Current assets | 181,149 | 157,426
Creditors: Amounts falling due within one year | (111,876) | (82,986)
Total assets less current liabilities | 69,273 | 74,440
Accruals and deferred income | (240) | (18,022)
| 69,033 | 56,418
Capital and reserves | 69,033 | 56,418

1 | General information

The company is a private company limited by share capital, incorporated in UK.

The address of its registered office is:
10 Linkfield Lane
Redhill
Surrey
RH1 1JL

These financial statements were authorised for issue by the director on 23 February 2026.

Basis of preparation

The financial statements have been prepared under the historical cost convention and in accordance with FRS 105 'The Financial Reporting Standard applicable to the Micro-entities Regime'.

2 | Staff numbers

The average number of persons employed by the company (including the director) during the year, was 0 (2024 - 4).

For the financial year ending 31 May 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the micro-entity provisions of the Companies Act 2006 and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Korlyns Therapeutics Ltd

(Registration number: 6215455)
Balance Sheet as at 31 May 2025

Approved and authorised by the director on 23 February 2026

......................................... C Iriajen Director